Table 1.

Demographics, baseline characteristics, and clinical outcomes of hematological patients with SARS-CoV-2 infection.

	UPN1	UPN2	UPN3	UPN4	UPN5	UPN6	UPN7	UPN8
Sex	M	W	M	W	M	M	W	W
Age	61	63	52	64	54	55	58	56
Days from positive NAT to last seen or death	68	66	59	59	23	55	55	55
Days from positive NAT to first symptomsa	−5	−8	−1	N/A	−2	2	7	10
First symptoms	Fever, cough	Cough, diarrhea	Fever, malaise	None	Fever	Fever	Dyspnea	Dysgeusia, nausea
Hematological diseaseb	DLBCL (12 months continuous complete remission)	Coombs positive Evans syndrome, Hodgkin lymphoma (10 year continuous complete remission)	DLBCL	Multiple myeloma	AML-MRC, CRi (severe pancytopenia)	Follicular lymphoma	Lymphoid blast crisis of CML, HLA-identical unrelated donor alloHCT, molecular remission, chronic GvHD	AML-MRC, HLA-identical sibling donor alloHCT, acute skin GvHD
Specific hematologic therapy in the last 12 months before COVID-19 diagnosis	EPOCH-R, high-dose MTX	Eltrombopagc, prednisolonec, intravenous immunoglobulinsc	R-CHOP and pegfilgrastimc	RVD induction; high dose cyclophosphamide (priming therapy) and filgrastimc	daunorubicin, cytarabine (7 + 3 induction)	G-CHOP and lipegfilgrastimc	TBI 8 Gy, fludarabine, rabbit ATG, methotrexate (reduced-intensity myeloablative conditioning); dasatinib; methylprednisolone and cyclosporinec	High-dose cytarabine (consolidation); busulfan, fludarabine (myeloablative conditioning); mycophenolate mofetil and cyclosporinec
Relevant coexisting disorders	Secondary immunoglobulin deficiency	Iatrogenic Cushing’s syndrome, Parkinson’s disease, severe osteoporosis, recurrent deep vein thrombosis, splenectomy	Obesity	None	Diabetes mellitus, peptic ulcer disease	Chronic obstructive pulmonary disease, arterial hypertension, clear cell renal cell carcinoma (in remission), obesity	Arterial hypertension, QTc-prolongation, extrapulmonary tuberculosis	Arterial hypertension, paroxysmal atrial fibrillation, hyperlipidemia
Smoking history	No	No	No	No	No	Yes, 122 pack years	No	No
All symptoms	Fever, cough, sore throat, respiratory distress	Fever, cough, dyspnea, diarrhea	Fever, mailase, cough, respiratory distress	None	Fever, cough, respiratory distress	Fever, cough, dysgeusia, respiratory distress	Dyspnea, cough, malaise, fever, respiratory distress	Dysgeusia, nausea, cough, fever, respiratory distress
Chest X-ray	Bilateral pneumonia	None	Bilateral pneumonia	None	Bilateral pneumonia	Bilateral pneumonia	Bilateral pneumonia	Bilateral pneumonia
Abnormal blood countd before SARS-CoV-2 infection	Lymphopenia	Leukocytosis	Lymphopenia	Severe neutropenia, mild anemia, severe thrombocytopenia, lymphopenia	Severe pancytopenia, lymphopenia	No	Anemia	Anemia, lymphopenia, thrombocytopenia
Laboratory changes since SARS-CoV-2 infection	Increased CRP, d-dimers, ferritin, LDH, PCT (IL-6, sIL-2R not measured)	Lymphocytosis, thrombocytopenia; increased IL-6 (ferritin, sIL-2R not measured)	Neutropenia, thrombocytopenia; increased AST, ALT, CRP, d-dimers, ferritin, HSTT, IL-6, LDH, PCT, sIL-2R	Increased CRP (ferritin, IL-6 and sIL-2r not measured)	Increased CRP, d-dimers, ferritin, HSTT, IL-6, LDH, sIL-2R; decreased fibrinogen	Neutropenia, thrombocytopenia, lymphocytopenia; increased AST, ALT, CRP, d-dimers, ferritin, fibrinogen, HSTT, IL-6, LDH (sIL-2R not measured)	Lymphocytopenia; increased CRP, ferritin, IL-6, sIL-2R	Increased CRP, ferritin, IL-6 (sIL-2R not measured)
Complications	Bacterial pneumonia	None	Severe ARDS, cytokine release syndrome, ventilator associated pneumonia	None	Severe ARDS, extubation failure, cytokine release syndrome, multi organ failure, death	Severe ARDS, cytokine release syndrome	None	CMV reactivation, bacterial enterocolitis
Days to ARDSe	N/A	N/A	7	N/A	7	6	N/A	N/A
Treatment of COVID-19	Hydroxychloroquine, clarithromycin, zinc	None	Hydroxychloroquine, azithromycin, zinc, tocilizumab (three doses), prednisolone, convalescent plasma with prednisolone	None	Hydroxychloroquine, azithromycin, zinc, tocilizumab (three doses), dexamethasone	Hydroxychloroquine, azithromycin, zinc, tocilizumab (two doses), convalescent plasma with prednisolone	Hydroxychloroquine, zinc	Hydroxychloroquine, azithromycin, zinc
SARS-CoV-2 S1/S2 IgG (EIA) at time of last NAT	N/A	Positive	Weakly positive	N/A	N/A	Negative	Negative	Positive
Days to negative NATf	11	N/R	34	7	N/R	48	N/R	N/R
Outcome	Cured, well, discharged	Alive, well, outpatient	Cured, well, rehabilitation	Cured, well, outpatient	Dead	Cured, well, rehabilitation	Alive, well, discharged	Alive, well, discharged

AlloHCT allogeneic hematopoietic cell transplantation, ALT alanine aminotransferase, AML-MRC acute myeloid leukemia with myelodysplasia-related changes, ARDS acute respiratory distress syndrome, AST aspartate aminotransferase, ATG anti-thymocyte globulin, CRi complete remission with incomplete hematologic recovery, CRP C-reactive protein, CML chronic myeloid leukemia, DLBCL diffuse large B-cell lymphoma, EIA enzyme immunoassay, EPOCH-R etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin, rituximab, G-CHOP obinutuzumab, cyclophosphamide, doxorubicin, vincristine, prednisolone, GvHD graft versus host disease, HLA human leukocyte antigen, HSTT highly sensitive troponin t, IgG immunoglobulin G, IL-6 interleukin-6, LDH lactate dehydrogenase, NAT nucleic acid test, N/A not applicable, N/R not reached, PBSC peripheral blood stem cell, PCT procalcitonin, R-CHOP rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone, RVD lenalidomide, bortezomib, dexamethasone, sIL-2R soluble interleukin-2 receptor, TBI total body irradiation, UPN unique patient number.

^aSome patients were identified by NAT screening after contact with infected patient before development of symptoms.

^bHematologic disease were classified according to WHO classification.

^cAdministered in the 14 days prior to COVID-19 onset.

^dLymphocytopenia was defined as a lymphocyte count of <1000 per cubic millimeter. Thrombocytopenia was defined as a platelet count of <150,000 per cubic millimeter.

^eDays to ARDS were counted from onset of clinical symptoms.

^fDays to negative NAT were counted from first positive NAT until the first of two consecutive negative NAT 24 h apart.